Lucid Diagnostics will hold a business update conference call on March 28, 2022 | Business


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the companies will host a commercial updates on Monday, March 28, 2022, at 4:30 p.m. EDT. During the call, Lishan Aklog, MD, President and CEO, will provide a business update, including an overview of near-term milestones and the company’s growth strategy. Additionally, Dennis McGrath, CFO of Lucid, will discuss the companies’ financial results for the fourth quarter of 2021.

To access the conference call, US-based listeners should dial 877-407-0789 and international listeners should dial 201-689-8562. All listeners must provide the operator with the conference call name “Lucid Business Update Conference Call” to join. Those interested in listening to the conference call live via webcast can do so by visiting the Investor Relations section of the Company’s website at

At the end of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 from within the United States or 412-317-6671 from outside the United States. To access the replay, all listeners must provide the following personal identification number: 13727145. The webcast will be available for replay in the Investor Relations section of the Company’s website at .

About Lucid

Lucid Diagnostics Inc is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. Lucid focuses on the millions of patients with gastroesophageal disease (GERD), also known as heartburn. chronic stomach conditions, which are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on specimens collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer death through early detection of esophageal precancer in patients at risk for GERD. EsoGuard is marketed in the United States as a laboratory developed test (LDT). EsoCheck is marketed in the United States as a 510(k) cleared esophageal cell collection device. EsoGuard, used with EsoCheck, has received FDA Breakthrough Device designation and is undergoing two large, international, active-enrollment, multi-center clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Testing Centers where patients at risk for GERD can undergo the EsoCheck procedure for EsoGuard testing. For detailed information about EsoGuard, please visit and follow us on TwitterFacebook and Instagram.

Forward-looking statements

This press release contains forward-looking statements. Forward-looking statements are all statements that are not historical facts. These forward-looking statements, which are based on the current beliefs and expectations of Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The risks and uncertainties that could cause such differences include, among others, the volatility of the market price of Lucid’s common stock; general economic and market conditions; uncertainties inherent in research and development, including the cost and time required to advance Lucid’s products through regulatory filing; whether regulatory authorities will be satisfied with the design and results of clinical and preclinical studies of Lucid; if and when Lucid’s products are cleared by regulatory authorities; market acceptance of Lucid’s products once approved and commercialized; Lucid’s ability to raise additional funds as needed; and other competitive developments. Additionally, Lucid is monitoring the COVID-19 pandemic and the impact of the pandemic on Lucid’s business. Lucid expects the significance of the COVID-19 pandemic, including the extent of its effects on its financial and operating results, to be dictated by, among other things, the success of efforts to contain the pandemic and the impact of these efforts on Lucid’s business. These factors are difficult or impossible to accurately predict and many of them are beyond Lucid’s control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a more detailed listing and description of these and other material risks and uncertainties that could affect Lucid’s future operations, see Lucid’s Registration Statement No. 333-259721 filed with the Securities and Exchange Commission. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions or circumstances on which such expectations may be based, or which may affect the likelihood that actual results different. of those contained in the forward-looking statements.

See the source version on

CONTACT: Investors

Adrian K. Miller

PAVmed inc.

[email protected]

Shani Lewis


(609) 516-5761

[email protected]



SOURCE: Lucid Diagnostics Inc.

Copyright BusinessWire 2022.

PUBLISHED: 07/03/2022 08:30/DISC: 07/03/2022 08:32

Recent stories you might have missed

Copyright BusinessWire 2022.

Michael P. Boser